Literature DB >> 11120899

Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.

A Kamachi1, M Munakata, Y Nasuhara, M Nishimura, Y Ohtsuka, M Amishima, T Takahashi, Y Homma, Y Kawakami.   

Abstract

BACKGROUND: Goblet cell hyperplasia (GCH) is a prominent feature in animal models of atopic asthma produced by immunisation and following multiple challenges with antigens. The aim of this study was to examine the effect of a beta(2) agonist on the development of GCH induced by the immune response.
METHODS: Brown Norway rats were immunised and challenged with an aerosol of ovalbumin for four weeks. Salbutamol (0.5 mg/kg/day) or vehicle was continuously delivered for the four weeks using a subcutaneously implanted osmotic minipump. The density of goblet cells, other morphological changes, and airway responsiveness to methacholine were evaluated 24 hours after the final challenge.
RESULTS: Treatment with salbutamol induced a more than twofold increase in the mean (SE) number of goblet cells (53.7 (7.3) vs 114.5 (11.8) cells/10(3) epithelial cells, p<0.01) while it did not significantly influence airway wall thickening and eosinophilic infiltration. Airway responsiveness to methacholine expressed as the logarithmic value of the concentration of methacholine required to generate a 50% increase in airway pressure (logPC(150)Mch) was also enhanced by the beta(2) agonist (-0.56 (0. 21) vs -0.95 (0.05), p<0.05). Additional experiments revealed that the same dose of the beta(2) agonist alone did not cause GCH in non-immunised rats and that the enhancement of GCH by salbutamol was completely abolished by simultaneous treatment with methylprednisolone (0.5 mg/kg/day).
CONCLUSIONS: These data suggest that salbutamol enhances goblet cell hyperplasia and airway hyperresponsiveness in this rat model of atopic asthma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120899      PMCID: PMC1745918          DOI: 10.1136/thorax.56.1.19

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  33 in total

Review 1.  Functional antagonism: tolerance produced by inhaled beta 2 agonists.

Authors:  D W Cockcroft; V A Swystun
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

2.  Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation.

Authors:  M Shichijo; Y Shimizu; K Hiramatsu; N Inagaki; K Tagaki; H Nagai
Journal:  Int Arch Allergy Immunol       Date:  1997-12       Impact factor: 2.749

3.  Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells.

Authors:  E Y Bissonnette; A D Befus
Journal:  J Allergy Clin Immunol       Date:  1997-12       Impact factor: 10.793

4.  Epidermal growth factor system regulates mucin production in airways.

Authors:  K Takeyama; K Dabbagh; H M Lee; C Agustí; J A Lausier; I F Ueki; K M Grattan; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  Salbutamol-induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect.

Authors:  K H Buchheit; A Hofmann; J R Fozard
Journal:  Eur J Pharmacol       Date:  1995-12-04       Impact factor: 4.432

6.  Lung inflammation and epithelial changes in a murine model of atopic asthma.

Authors:  D I Blyth; M S Pedrick; T J Savage; E M Hessel; D Fattah
Journal:  Am J Respir Cell Mol Biol       Date:  1996-05       Impact factor: 6.914

7.  Interleukin-13: central mediator of allergic asthma.

Authors:  M Wills-Karp; J Luyimbazi; X Xu; B Schofield; T Y Neben; C L Karp; D D Donaldson
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

8.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

9.  Induction, duration, and resolution of airway goblet cell hyperplasia in a murine model of atopic asthma: effect of concurrent infection with respiratory syncytial virus and response to dexamethasone.

Authors:  D I Blyth; M S Pedrick; T J Savage; H Bright; J E Beesley; S Sanjar
Journal:  Am J Respir Cell Mol Biol       Date:  1998-07       Impact factor: 6.914

10.  TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma.

Authors:  M Mathur; K Herrmann; X Li; Y Qin; J Weinstock; D Elliott; J Monahan; P Padrid
Journal:  Am J Respir Crit Care Med       Date:  1999-02       Impact factor: 21.405

View more
  12 in total

Review 1.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice.

Authors:  Rui Lin; Simone Degan; Barbara S Theriot; Bernard M Fischer; Ryan T Strachan; Jiurong Liang; Richard A Pierce; Mary E Sunday; Paul W Noble; Monica Kraft; Arnold R Brody; Julia K L Walker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Chronic β2AR stimulation limits CFTR activation in human airway epithelia.

Authors:  John J Brewington; Jessica Backstrom; Amanda Feldman; Elizabeth L Kramer; Jessica D Moncivaiz; Alicia J Ostmann; Xiaoting Zhu; L Jason Lu; John P Clancy
Journal:  JCI Insight       Date:  2018-02-22

Review 4.  Beta2-agonists and bronchial hyperresponsiveness.

Authors:  Clive P Page; Domenico Spina
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

5.  Asthma treatment through the beta receptor: lessons from animal models.

Authors:  Erik P Riesenfeld; Charles G Irvin
Journal:  Front Biosci (Elite Ed)       Date:  2011-06-01

Review 6.  Mucus hypersecretion in asthma: causes and effects.

Authors:  Christopher M Evans; Kyubo Kim; Michael J Tuvim; Burton F Dickey
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

7.  Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease.

Authors:  Erik P Riesenfeld; Michael J Sullivan; John A Thompson-Figueroa; Hans C Haverkamp; Lennart K Lundblad; Jason H T Bates; Charles G Irvin
Journal:  Respir Res       Date:  2010-02-24

8.  β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility.

Authors:  Long P Nguyen; Nour A Al-Sawalha; Sergio Parra; Indira Pokkunuri; Ozozoma Omoluabi; Adedoyin A Okulate; Elizabeth Windham Li; Matthew Hazen; Jose M Gonzalez-Granado; Craig J Daly; John C McGrath; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

9.  Progressive severe lung injury by zinc oxide nanoparticles; the role of Zn2+ dissolution inside lysosomes.

Authors:  Wan-Seob Cho; Rodger Duffin; Sarah E M Howie; Chris J Scotton; William A H Wallace; William Macnee; Mark Bradley; Ian L Megson; Ken Donaldson
Journal:  Part Fibre Toxicol       Date:  2011-09-06       Impact factor: 9.400

10.  Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma.

Authors:  Michela Bullone; Amandine Vargas; Yvonne Elce; James G Martin; Jean-Pierre Lavoie
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.